摘要
肿瘤患者凝血系统常被激活而处于高凝状态,易于形成血栓。静脉血栓事件的防治是目前肿瘤研究中的热点。近年来有研究表明低分子肝素在治疗肿瘤患者深静脉血栓形成的同时能延长患者的生存。本文简要综述有关低分子肝素抗凝治疗延长肿瘤患者生存及其分子机制的研究进展。
The blood coagulation system is always activated in cancer patients and hypercoagulative state tends to cause thrombosis.Recent studies has showed that low molecular weight heparin for the initial treatment of deep vein thrombosis can improve the survival of cancer patients.In this review we briefly summarize the advance of low molecular weight heparin treatment on survival of cancer patients and the molecular mechanism involved.
出处
《临床肿瘤学杂志》
CAS
2011年第12期1142-1145,共4页
Chinese Clinical Oncology
关键词
低分子肝素
深静脉血栓形成
血管新生
增殖
凋亡
Low-molecular-weight heparin
Deep vein thrombosis
Angiogenesis
Proliferation
Apoptosis
